This disease has important personal, social, and financial consequences for patients, their families, and health care systems. This chronic demyelinating disease is characterized by a varied clinical expression with an unpredictable course and a variable prognosis. Multiple sclerosis is an inflammatory autoimmune disorder of the central nervous system (CNS) and the most common cause of progressive neurological disability in young adults. ConclusionĪpproximately two-thirds of patients newly diagnosed with MS did not receive a DMT and the disease is accompanied by a significant comorbid burden. Glatiramer and dimethyl fumarate were by far the most common first-line treatments received accounting for nearly 62% of patients receiving a DMT. Use of more than one DMT concomitantly occurred in just 1.8% of all treated patients. Of those receiving a DMT, 28.2% went on to receive a second line of therapy, 5.8% received a third, and just 0.9% went on to a fourth line. Just 1994 (35.0%) of patients received a DMT at any time during follow-up. Common comorbidities included physical symptoms (e.g., pain, weakness, fatigue), mental health conditions (anxiety, depression), and cardiovascular/metabolic conditions (hypertension, hyperlipidemia, diabetes, obesity). We identified 5691 patients with incident MS.
Presence of comorbid conditions were captured during the one year prior to and following (and including) the index date absolute change in prevalence from the pre- to post-index periods was calculated. Treatment sequences were captured for all available disease modifying therapies (DMTs) during all available follow-up.
Patients were required to have enrollment in the database ≥1 year prior to and ≥ 1 year following their first MS diagnosis. Patients had ≥2 diagnoses for MS or an inpatient hospitalization with a primary diagnosis of MS. Patients with incident MS were identified from a large national claims database during –. Understanding real-world treatment patterns of patients is necessary to identifying potential gaps in care. The treatment landscape for multiple sclerosis (MS) is quickly evolving.
0 kommentar(er)
